| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
MTH1 (MutT homolog 1, NUDT1).
|
|---|---|
| ln Vitro |
With IC50 values of 1.38, 0.83, 1.03, 1.08, 1.72, and 0.8 μM, TH588 (2-10μM; 7-10 days) effectively and selectively kills HeLa, MDA-MB-231, MCF-7, SW480, and SW620 cells [1].
TH588 hydrochloride is a potent MTH1 inhibitor with a Kd of 15.5 nM and low nanomolar IC50. It is approximately 20-fold less potent against mouse MTH1 compared to human, rat, pig, and dog MTH1. The compound selectively kills cancer cells by incorporating oxidized dNTPs into DNA, leading to DNA damage and mitotic catastrophe. |
| ln Vivo |
In the SW480 xenograft cancer model, TH588 (30 mg/kg; subcutaneous injection; once daily for 35 days) inhibits the growth of tumors [1].
TH588 has shown promise in preclinical cancer studies but its targeting specificity has been questioned. It is a microtubule-modulating agent that eliminates cancer cells by activating the mitotic surveillance pathway. TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia and has cytotoxic effects on transformed cells. |
| Enzyme Assay |
The MTH1 enzymatic assay uses recombinant MTH1 and 8-oxo-dGTP as substrate. Hydrolysis of 8-oxo-dGTP to 8-oxo-dGMP is measured by HPLC or a coupled enzyme assay. Test compounds are incubated with the enzyme and substrate, and IC50 values are determined from inhibition curves.
|
| Cell Assay |
Cell viability assay[1]
Cell Types: U2OS, HeLa, MDA-MB-231, MCF-7, SW480, SW620, VH10, HDFn Cell Tested Concentrations: 2, 4, 6, 8, 10 μM Incubation Duration: 7–10 days Experimental Results: Selectively and effectively kill U2OS, HeLa, MDA-MB-231, MCF-7, SW480 and SW620 cells, with IC50 of 1.38, 0.83, 1.03, 1.08, 1.72, 0.8 μM respectively, but it is toxic to several primary cells. smaller. or immortalized cells. In cellular assays, cancer cell lines are treated with TH588 hydrochloride. Cell viability is measured using a viability assay. DNA damage is assessed by measuring 8-oxodG incorporation into DNA using immunohistochemistry or mass spectrometry. Mitotic progression is evaluated by flow cytometry or time-lapse microscopy. |
| Animal Protocol |
Animal/Disease Models: 5-6 weeks female SCID (severe combined immunodeficient) mouse (SW480 xenograft cancer model) [1]
Doses: 30 mg/kg Route of Administration: subcutaneous injection; one time/day for 35 days Experimental Results: SW480 xenograft cancer model tumor growth was diminished. In vivo studies use mouse xenograft models. TH588 is administered orally or systemically, and tumor growth inhibition is measured. MTH1 target engagement and DNA damage markers in tumor tissue are assessed by immunohistochemistry. The compound is also evaluated in combination with ionizing radiation. |
| References |
[1]. Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508(7495):215-21.
|
| Molecular Formula |
C13H13CL3N4
|
|---|---|
| Molecular Weight |
331.62811923027
|
| Exact Mass |
330.02
|
| CAS # |
1640282-30-9
|
| Related CAS # |
TH588;1609960-31-7
|
| PubChem CID |
91826507
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
313
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC1N=C(NC2CC2)C=C(C2C(Cl)=C(Cl)C=CC=2)N=1.[H]Cl
|
| InChi Key |
FBHMEHNWFXCSKE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H12Cl2N4.ClH/c14-9-3-1-2-8(12(9)15)10-6-11(17-7-4-5-7)19-13(16)18-10;/h1-3,6-7H,4-5H2,(H3,16,17,18,19);1H
|
| Chemical Name |
4-N-cyclopropyl-6-(2,3-dichlorophenyl)pyrimidine-2,4-diamine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0154 mL | 15.0770 mL | 30.1541 mL | |
| 5 mM | 0.6031 mL | 3.0154 mL | 6.0308 mL | |
| 10 mM | 0.3015 mL | 1.5077 mL | 3.0154 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
